Dr.Sharmistha Behera, B09184
ABSTRACT PURPOSETo evaluate the efficacy of subconjunctival bevacizumab injection in preventing postoperative pterygium recurrence.METHODS 1 year prospective comparative study.Patients were randomly categorized into 2 groups Study group received 1.25 mg/0.05 ml subconjunctival bevacizumab 1 week before pterygium surgery Both groups underwent pterygium excision with conjunctival autograft.The main outcome was the change in size and clinical appearance.Treatment-related complications and adverse events were reported.RESULTS There was statistically significant improvement in grade, color intensity, size of pterygium, and symptoms of patients.Recurrence was noted in five patients (10%) in total study population at the end of 3 months.CONCLUSIONSSubconjunctival bevacizumab injection is useful in preventing recurrence of pterygium, with no significant local or systemic adverse effects.
PRESENTATION NOT RECEIVED FROM THE AUTHOR.
Leave a Comment